Shanghai MicroPort EP MedTech Announces First Case of the Clinical Trial Of FlashPoint™ Renal Artery RF Ablation System

On 12 December 2013, Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that it has completed the first case of the clinical trial of FlashPoint™ Renal Artery RF Ablation System in which the case was performed under the affiliation with Guangxi Medical University by Professor Lang Li. FlashPoint™ is independently developed by Shanghai MicroPort EP MedTech. "This is a prospective, multicenter, randomized controlled clinical trial and the successful completion of the first clinical trial case suggests that it has formally entered into clinical research stage," said Dr. Yiyong Sun, the President of Shanghai MicroPort EP MedTech. "MicroPort EP MedTech will be further working on the development of the product and provide better options for patients with treatment-resistant hypertension."